Abstract
Background Numerous models have tried to predict the spread of COVID-19. Many involve myriad assumptions and parameters which cannot be reliably calculated under current conditions. We describe machine-learning and curve-fitting based models using fewer assumptions and readily available data.
Methods Instead of relying on highly parameterized models, we design and train multiple neural networks with data on a national and state level, from 9 COVID-19 affected countries, including Indian and US states and territories. Further, we use an array of curve-fitting techniques on government-reported numbers of COVID-19 infections and deaths, separately projecting and collating curves from multiple regions across the globe, at multiple levels of granularity, combining heavily-localized extrapolations to create accurate national predictions.
Findings We achieve an R2 of 0·999 on average through the use of curve-fits and fine-tuned statistical learning methods on historical, global data. Using neural network implementations, we consistently predict the number of reported cases in 9 geographically- and demographically-varied countries and states with an accuracy of 99·53% for 14 days of forecast and 99·1% for 24 days of forecast.
Interpretation We have shown that curve-fitting and machine-learning methods applied on reported COVID-19 data almost perfectly reproduce the results of far more complex and data-intensive epidemiological models. Using our methods, several other parameters may be established, such as the average detection rate of COVID-19. As an example, we find that the detection rate of cases in India (even with our most lenient estimates) is 2.38% - almost a fourth of the world average of 9% [1].
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no external funding provided for this study and the authors used personal resources to carry out this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The corresponding author confirms that he had full access to all data in this study and had final responsibility for submitting this manuscript for publication. All data has been taken from publicly available repositories. All the code used in the manuscript is provided in a public repository.
https://ourworldindata.org/coronavirus
https://github.com/nytimes/covid-19-data
